Analysis on whether Roprostim (Huierning) needs to be taken continuously for a long time

Romiplostim (Romiplostim) is an injectable recombinant thrombopoietin receptor agonist (TPO-RA). By binding to the TPO receptor on the surface of megakaryocytes in the bone marrow, it promotes the maturation of megakaryocytes and the release of platelets, thereby increasing the number of platelets in peripheral blood. This drug is widely used to treat patients with chronic immune thrombocytopenia (ITP), especially those who are refractory to or intolerant to glucocorticoids, immunoglobulins, or splenectomy. Since ITP is a chronic immune-mediated disease, the therapeutic purpose of loplastin is usually to maintain platelets at a safe level for a long time rather than to cure the disease.

In clinical practice, whether loplastin needs to be taken for a long time depends on the patient's underlying disease course and response to the drug. In some patients, after weeks or months of treatment, their platelet levels stabilize and can remain normal after stopping the drug. Such patients can try to gradually reduce the dose or stop the drug; however, most patients with chronic ITP will have a decrease in platelets after stopping the drug, so they need to continue long-term treatment to prevent the risk of bleeding. The goal of long-term use is not to increase platelets indefinitely, but to maintain a safe range above 50×10⁹/L, thereby reducing spontaneous bleeding without increasing the risk of thrombosis.

The treatment regimen of Roprostim is usually a once-weekly subcutaneous injection, with the dose dynamically adjusted based on platelet count. If the patient responds well to the drug and has no serious adverse reactions, the treatment can be maintained for a long time. Clinical studies have shown that some patients may experience "immune tolerance reconstitution" after continuous use for 1 to 2 years, that is, platelets can still maintain a stable level even after stopping the drug, which suggests that a small number of patients may achieve "functional remission." However, there are currently no clear biological markers that predict which patients will successfully discontinue the drug, so doctors often recommend attempts at tapering with close monitoring.

In general, loplastin is a long-term maintenance treatment drug for mostITP patients, and its safety and effectiveness have been verified in long-term clinical follow-up. In order to ensure the efficacy and avoid adverse reactions, patients need to regularly monitor platelet count, liver function and bone marrow status to avoid increasing the risk of thrombosis due to excessive elevation of platelets. At the same time, patients should avoid stopping the medication or changing the dosage without authorization, and follow the individualized treatment plan prescribed by the doctor. Through scientific, regular and continuous treatment management, loplastin can help ITP patients achieve stable platelet levels and better quality of life.

Reference materials:https://www.drugs.com/